P-TEFb goes viral

Justyna Zaborowska1), Nur F. Isa1)2) and Shona Murphy1)*

Positive transcription elongation factor b (P-TEFb), which comprises cyclin-dependent kinase 9 (CDK9) kinase and cyclin T subunits, is an essential kinase complex in human cells. Phosphorylation of the negative elongation factors by P-TEFb is required for productive elongation of transcription of protein-coding genes by RNA polymerase II (pol II). In addition, P-TEFb-mediated phosphorylation of the carboxyl-terminal domain (CTD) of the largest subunit of pol II mediates the recruitment of transcription and RNA processing factors during the transcription cycle. CDK9 also phosphorylates p53, a tumor suppressor that plays a central role in cellular responses to a range of stress factors. Many viral factors affect transcription by recruiting or modulating the activity of CDK9. In this review, we will focus on how the function of CDK9 is regulated by viral gene products. The central role of CDK9 in viral life cycles suggests that drugs targeting the interaction between viral products and P-TEFb could be effective anti-viral agents.

Keywords:
- CDK9; CTD; EBV; HIV; HSV; HTLV; P-TEFb

Introduction

Transcription of many human viruses is dependent on host cell factors such as RNA polymerase II (pol II) [1]. Pol II is made up of 12 subunits (Rpb1–Rpb12) [2]. The carboxyl-terminal domain (CTD) of the largest subunit of pol II (Rpb1) comprises tandemly repeated heptapeptides with the consensus sequence Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 [3, 4]. The CTD plays a central role in transcriptional and co-transcriptional RNA processing [4–7] by mediating the recruitment of transcription and processing factors at different steps of the transcription cycle through reversible modification of the residues within the heptapeptide repeats [8]. CTD modification generates a code that regulates the interaction with transcription and RNA processing factors [9–12]. Among the CTD modifications, the phosphorylation of Ser2 (Ser2P) of pol II CTD, is catalyzed by the cyclin-dependent kinase 9 (CDK9) subunit of the positive transcription elongation factor b (P-TEFb). P-TEFb also phosphorylates two negative transcription elongation factors: DRB sensitivity-inducing factor (DSIF) and negative elongation factor (NELF), which are recruited to the elongation complex in the promoter proximal region to induce pol II pausing [13, 14]. Phosphorylation of NELF promotes its dissociation from the elongation complex, whereas phospho-DSIF remains associated with pol II as an elongation activator [14]. The role of P-TEFb in stimulating productive elongation was elucidated using 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), which is a purine nucleoside analog that inhibits CDK9 activity [15]. Treatment of cells with DRB results in the production of shortened transcripts, diagnostic of the inability of pol II to transcribe through the early elongation checkpoint in the absence of P-TEFb activity [16]. In addition to Serz of the pol II CTD, NELF and DSIF, several serine residues in the key transcription factor p53 are phosphorylated by CDK9, which results in p53 activation [17, 18].

Positive transcription elongation factor b comprises the CDK9 kinase and a cyclin partner [15]. CDK9 is an ubiquitously expressed Ser/Thr proline-directed kinase [19, 20]. It was identified in the early 1990s and initially named PITALRE [19, 21]. It exists in two isoforms, CDK9-42 and CDK9-55, which arise from two transcription start sites [22]. The ratio of CDK9-42/CDK9-55 is cell type-dependent [23], and it is unclear if there are functional differences between the two isoforms. CDK9 interacts with T-type cyclins – T1, T2a, T2b and cyclin K [24, 25]. In this heterodimer, the CDK9 subunit provides the enzymatic activity, while the cyclin has a regulatory role [24, 26]. However, mass spectrometry has failed to demonstrate that cyclin K is associated with CDK9 [27]. In addition, a recent study revealed that cyclin K associates with CDK12 and CDK13 [28]. Therefore, cyclins T1 and T2 may be the major cyclins associated with CDK9. In the cell, P-TEFb exists in two major forms. A large amount of cellular P-TEFb is sequestered in an inactive complex with the noncoding 7SK small nuclear RNA (7SK snRNA), hexamethylene bisacetamide-induced protein 1 (HEXIM1) and/or HEXIM2 and the La-related protein 7 [29–35]. The catalytically active form of P-TEFb is instead generally associated with bromodomain-containing protein 4 (Brd4) and the super elongation complex (SEC) [36–38]. The transition between active and inactive forms is dynamic and tightly regulated [37, 38], reflecting the important role that P-TEFb plays in cellular processes (Fig. 1). Given the importance of P-TEFb in regulating cellular gene expression, it is perhaps not surprising that this complex is also functionally integrated into the expression of human viruses (Table 1). Several viral factors regulate CTD phosphorylation through recruitment or modulation of the activity of CDK9.

The studies reviewed here present examples of DNA and RNA viruses that subvert the host cell CTD kinase CDK9 for

DOI: 10.1002/icl3.1037
their own needs. Understanding the requirements of CDK9 for viral infection and how viral infection alters pol II CTD phosphorylation patterns not only advances our knowledge of viral pathogenesis but also provides potential new anti-viral drug targets.

The α-herpesvirus ICP22 protein has an intimate relationship with P-TEFb

After infection, herpes simplex virus (HSV-1 and HSV-2) goes through a lytic replicative phase and causes localized lesions. This is followed by a latent phase where viruses reside in sensory neurons and can be frequently reactivated by a range of stresses, including high temperature and ultraviolet light [39]. Although HSV infections are generally self-limiting in healthy individuals, they can cause cancer, inflammation of the brain and the eye, and pose a significant mortality risk in infants and immuno-compromised adults [40, 41]. The HSV immediate-early protein 22 (ICP22) is encoded by the US1 gene and comprises 420 amino acid residues. Viral deletion mutants without the US1 gene have a reduced capacity to establish latency in animal models [42, 43]. In addition, deletion of this gene causes viral growth defects in some cell lines [42]. During HSV-1 productive infection, three classes of genes are sequentially expressed; first, the immediate-early genes (α-genes), next, the early genes (β-genes), and finally, the late genes (γ-genes) [44, 45]. It has been demonstrated that ICP22 represses transcription of the viral α-genes, β-genes and γ-genes by blocking the recruitment of P-TEFb to their promoters. In contrast, the herpes viral protein 16 (VP16) overcomes the inhibitory effects of ICP22 on α-gene transcription [46]. It has been demonstrated that ICP22 alters the CTD phosphorylation

---

**Table 1. Viral factors that interact with P-TEFb**

| Virus                  | Viral factors that interact with P-TEFb | References |
|------------------------|-----------------------------------------|------------|
| Herpes simplex virus   | ICP22                                   | [50, 142]  |
| Human cytomegalovirus  | pUL69                                   | [69, 70, 143] |
| Epstein–Barr virus     | EBNA2                                   | [75]       |
| Human immunodeficiency virus | Tax                            | [114, 145] |
| Human T-lymphotropic virus | Tax                          | [110, 111] |
| Human adenovirus       | E1A                                     | [117]      |
| Influenza A virus      | vRNP                                    | [121]      |
| Dengue virus           | DENV core protein                       | [129]      |
| Kaposi’s sarcoma-assoc. | K-cyclin                               | [59]       |

P-TEFb, positive transcription elongation factor b; ICP22, immediate-early protein 22; EBNA2, Epstein–Barr nuclear antigen 2; vRNP, viral RNA-dependent RNA polymerases.

---

**Figure 1.** The role of positive transcription elongation factor b (P-TEFb) in a regulation of pol II transcription. P-TEFb, comprising cyclin-dependent kinase 9 (CDK9) and a cyclin T1 subunit, exists in a catalytically inactive small nuclear ribonucleic particle with 7SK snRNA and HEXIM1. Active P-TEFb is bound instead to bromodomain-containing protein 4 (Brd4) and stimulates elongation through phosphorylation of the pol II carboxyl-terminal domain (CTD) on Ser2 and two negative transcription elongation factors: DRB sensitivity-inducing factor (DSIF) and negative elongation factor (NELF). Phosphorylation converts DSIF from a repressor to an activator, whereas phosphorylated NELF leaves the elongation complex.

---

**Review Article**
state of pol II [47]. ICP22 mediates two distinct effects on pol II: the induction of an intermediately migrating form of pol II (pol IIi) and the loss of pol II forms phosphorylated on Ser2 [47, 48]. Pol IIi replaces the normal hyperphosphorylated form of pol II in HSV-1 infected cells. The induction of pol IIi requires ICP22 and another viral factor, UL13 [49]. A recent study demonstrated that ICP22 interacts directly with cellular CDK9 and that a short segment of ICP22 (residue 193-256) is sufficient for this interaction [50]. However, this short segment does not interact with pol II, unlike the full length of ICP22. Nevertheless, ectopic expression of either full length of ICP22 or amino acids residues 193-256, leads to the loss of Ser2 CTD phosphorylation and subsequently to the inhibition of transcriptional elongation of host cell genes [50]. These findings suggest a model where ICP22 is recruited to the transcriptionally active host genes soon after infection, where its interaction with P-TEFb inhibits the kinase activity of CDK9, resulting in the loss of productive elongation (Fig. 2). Lytic infection with HSV-1 also causes transcription termination defects on host cell genes [51]. Termination of transcription of the viral genes is however, efficient, highlighting that HSV-1 proteins regulate transcription to maximize expression of the viral genome while down-regulating expression of the host genome. Shuting down host cell gene expression could benefit the virus by, for example, helping to evade anti-viral responses including production of type I interferon [52]. Interaction of ICP22 with the CDK9 target, p53, is also important for efficient HSV-1 replication [53].

KSHV factors regulate P-TEFb activity towards pol II and p53

Kaposi sarcoma-associated herpesvirus (KSHV) is also known as human herpesvirus 8. KSHV causes Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma [54–56]. K-cyclin, encoded by the virus, can interact and activate CDK6 and can trigger apoptosis in cells with high levels of this cyclin [57, 58]. In the search for new K-cyclin partners, CDK9 was identified as a new interacting CDK. In addition, it was demonstrated that K-cyclin stimulates CDK9 kinase activity towards p53, and that CDK9 is required for K-cyclin-induced p53-dependent growth suppression [59]. However, the role of CDK9 in KSHV replication goes beyond its interaction with K-cyclin. The replication and transcription activator (RTA) of KSHV, K-RTA, regulates the reactivation of KSHV from a latent state. As demonstrated by an in vitro kinase assay, RTA is a substrate of CDK9. Furthermore, CDK9 inhibitors suppress the expression of various K-RTA target genes. This further suggests that CDK9 inhibitors could be used to disturb KSHV replication [60]. Interestingly, transcription elongation of KSHV lytic genes is paused during latency and can be reactivated in an RTA-independent manner. Chip-on-chip analysis revealed that during KSHV latent infection, pol II transcription complexes are associated with NELF at the promoters of a group of lytic genes including OriLytL, K5, K6, and K7 (Fig. 3). The CTD of pol II at these promoters is hyperphosphorylated on Ser5 and hypophosphorylated of Ser2. It was hypothesized that hypophosphorylation of Ser2 might be due to the recruitment of enzymatically inactive P-TEFb to promoters [61]. Therefore, the negative control of transcriptional elongation of lytic gene expression by modulating CDK9 activity during KSHV latency could be a key regulatory mechanism.

P-TEFb is a key player in HCMV transcriptosomes

The β-herpesvirus human cytomegalovirus (HCMV), also known as human herpesvirus 5, infects 50–90% of the human population [62]. HCMV infections are the leading viral cause of birth defects and pose a significant mortality risk in immunosuppressed individuals. In addition, HCMV may contribute to atherosclerosis and restenosis after coronary atherectomy [62, 63].
HCMV infection results in the formation of viral transcriptosomes in the nucleus [64–66]. These are the sites of transcription of the viral immediate-early (IE) genes to which various viral and cellular factors are recruited [67]. Cellular transcription regulators present at these sites include pol II, CDK9, cyclin T1, CDK7, and Brd4 [65, 66, 68]. It is well documented that HCMV infection affects the level and kinase activity of the recruited CDKs [68]. In addition, recruitment of CDK9 to transcriptosomes during lytic infection results in hyperphosphorylation of the pol II CTD [66, 68, 69]. Increased CTD phosphorylation might provide docking sites for processing factors regulating the alternative splicing of the primary HCMV transcripts [68]. In addition, P-TEFb activity is associated with the regulatory functions of HCMV-encoded proteins pUL69, IE2-86, and pUL97 [67, 69, 70] and thus appears to be important for HCMV replication.

**P-TEFb is critical for immortalization of EBV-infected cells**

The Epstein–Barr virus (EBV), a γ-herpesvirus, is another important human pathogen, and seropositivity to EBV is estimated to be >90% in adults [71]. EBV is able to infect and immortalize human B-cells and is the causative agent of infectious mononucleosis [72, 73]. It has been also associated with several cancers, including Burkitt lymphoma and subsets of Hodgkin’s lymphomas and T-cell lymphomas [74]. One of the viral genes translated during latency and required for B-cell transformation and proliferation of infected cells is Epstein–Barr nuclear antigen 2 (EBNA2) [75]. EBNA2 is an activator of viral and cellular transcription, and P-TEFb is required for its activity [76–78]. EBNA2 activation is sensitive to inhibition by a dominant negative mutant of CDK9 and the CDK9 inhibitor DRB. In addition, EBNA2 promotes Ser5 phosphorylation of the pol II CTD [78]. EBNA2 activates transcription from the viral C promoter (Cp) generating a long primary transcript encoding nuclear antigens necessary for immortalization of the host cells. In addition, EBNA2 activates the promoters of viral latent membrane protein genes (LMP1, LMP2A, and LMP2B) [79–81]. Recently, Palermo et al. (2011) demonstrated that Cp directs the buildup of a high level of stalled pol II together with the pausing factors DSIF and NELF. The stalled pol II maintains a nucleosome-depleted region as measured by chromatin immunoprecipitation for histone H3. Moreover, stalled pol II increases recruitment of Brd4-associated P-TEFb to drive high levels of Ser2 phosphorylation of the pol II CTD and facilitate productive elongation [82]. These results highlight a key role for P-TEFb in EBNA2-dependent transcription activation and the immortalization of EBV-infected cells.

**HIV Tat effectively hijacks P-TEFb**

The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome [83]. The main target cells for HIV are CD4+ T lymphocytes and macrophages [84, 85]. The most extensively studied in vivo latent reservoir is found within memory CD4+ T cells [86]. HIV can also infect dendritic cells [87]. Activation of latent viruses occurs at the level of elongation of transcription and requires binding of the HIV-encoded elongation factor (Tat) to the transactivation response element at the start of HIV transcripts. The CDK9/cyclin T1 complex is an important factor for productive elongation of transcription of HIV genomes, and the inhibition of CDK9 can ameliorate HIV-induced disease in animal models [88]. In cultured human cells, dominant negative CDK9 mutants impair HIV-1 replication [89].

Multiple levels of regulation of P-TEFb impact HIV transcription. For example, P-TEFb activity can be regulated by...
phosphorylation/dephosphorylation of the CDK9 subunit \[90\], and phosphatases involved in this process have been implicated in regulating HIV transcription \[91, 92\]. HIV Tat targets CDK9/cyclin T1 to transactivation response element to stimulate transcription elongation through P-TEFb-dependent phosphorylation of NELF, DSIF, and Ser2 of pol II CTD \[93–95\]. Tat competes with HEXIM1 for binding to cyclin T1 to promote the dissociation of P-TEFb from the large inactive complex \[96\]. In order to further stimulate viral gene expression, Tat recruits additional host factors including the human SEC (Fig. 4). SEC contains a set of factors implicated in regulation of pol II transcription elongation, and its core components include the scaffold proteins AFF1 or AFF4, P-TEFb, elongation stimulatory factors ELL1 or ELL2, and transcription factors ENL and AF9 \[97–101\]. The function of the SEC is to stimulate elongation of transcription by increasing the processivity of pol II \[98\]. A recent study established that the AFF1-containing form of the SEC is more potent in supporting HIV-1 transactivation than AFF4-SEC \[101\]. The ELL1/ELL2 components of the SEC promote Tat transactivation by suppressing pol II pausing and ELL2 is more effective than ELL1 in Tat transactivation \[98\].

The crystal structure of Tat-P-TEFb \[102\] and the recently published Tat-AFF4-P-TEFb crystal structure \[103\] provide insights into the mechanism of Tat activation. Tat interacts with both cyclin T and CDK9 and induces conformational changes in P-TEFb upon binding. These structural studies can help in designing small-molecule compounds that disrupt the Tat-P-TEFb and the Tat-AFF4 interactions to specifically inhibit HIV transcription without affecting normal P-TEFb function. The central role that P-TEFb plays in Tat-dependent activation of latent HIV genomes makes CDK9 an attractive target for the development of novel HIV therapeutics.

**More P-TEFb please for HTLV-1 too**

Human T-lymphotropic virus type 1 (HTLV-1) infections cause several human diseases such as adult T-cell leukemia, the neurological disorder HTLV-1-associated myelopathy, and uveitis \[104–107\]. HTLV encodes a transcriptional transactivator protein called Tax, which functions as an activator of the long terminal repeat (LTR) promoter \[108, 109\]. Similarly to HIV-1 Tat, HTLV-1 Tax influences transcription by pol II \[110\]. P-TEFb is essential for Tax transactivation \textit{in vivo} and \textit{in vitro}, and siRNA treatment to CDK9 and the CDK9 inhibitor flavopiridol both inhibit transactivation by Tax \[110\]. \textit{In vitro} binding studies demonstrate that Tax competes with Brd4 for P-TEFb binding through direct interaction with cyclin T1. In addition, Tax overexpression decreases the amount of 7SK snRNA associated with P-TEFb and specifically stimulates Ser2 phosphorylation of the pol II CTD \[111\]. These events give rise to a functional Tax/P-TEFb complex for viral LTR activation (Fig. 5). As Brd4 competes with Tax for P-TEFb, LTR promoter activity is higher in HTLV-1-transformed Brd4-deficient cells \[112\]. Interestingly, a recent study showed that in common with HIV-1 Tat transactivation,
the ELL component of the pol II SEC is essential for Tax-mediated transactivation. Tax enhances ELL incorporation into the histone acetyltransferase p300 and P-TEFb transcriptional complexes. Depletion of ELL using an shRNA-mediated approach abrogates Tax transactivation [113]. Thus, the HTLV-1 virus uses similar strategies to HIV-1 to hijack cellular P-TEFb.

Inhibiting CDK9 blocks adenovirus replication

Human adenovirus (HAdV) is a double-stranded DNA virus that causes upper and lower respiratory infections [114]. The adenovirus large E1A (L-E1A) protein is a transcriptional activator that functions through the action of an activation domain named “conserved region 3” (CR3). CR3 has been shown to recruit cellular transcription factors including mediator subunit 23 (Med23) [115, 116]. Recent proteomic analysis in human cells infected with HAdV5 revealed that L-E1A is associated with many subunits of the mammalian mediator complex [117]. Interestingly, the presence of mediator subunits in the L-E1A protein complex is greatly reduced in cells depleted of Med23, suggesting that Med23 links the transactivation domain CR3 with the mediator complex. The proteomic analysis also revealed that L-E1A is associated with super elongation complex components, such as CDK9, cyclin T1, AFF4, ELL, and EAF. The catalytic constituent of the SEC, CDK9, was shown to be critical for the transcription of HAdV early genes by L-E1A and HAdV5 replication [117]. Interestingly, a newly developed CDK9 inhibitor, FIT-039 (N-[5-fluoro-2-(1-piperidinyl)phenyl]isonicotinitioamide), suppresses HAdV replication [118]. This further suggests that HAdV hijacks P-TEFb activity for viral-specific transcription.

P-TEFb influences influenza

The best-studied member of the orthomyxovirus RNA virus family is the influenza A virus, which is responsible for acute respiratory diseases in humans. After infection with influenza A, viral RNA-dependent RNA polymerases (vRNPs) are transported to the nucleus, where viral transcription takes place. vRNPs associate with the promoter region of protein-coding genes with lower levels in the regions downstream of the promoter [119]. This reflects the distribution of pol II in infected cells. In mock-infected and influenza virus-infected cells, there are similar levels of pol II associated with the promoter region of genes. However, in infected cells, there are decreased levels of pol II in coding regions suggesting that influenza virus infection inhibits pol II elongation [120]. Zhang et al. [121] demonstrated that CDK9/cyclin T1 interacts with the vRNP of influenza A virus and facilitates its association with cellular pol II phosphorylated on Ser2 of the CTD. CDK9 interacts with
three subunits of influenza virus vRNP, PB1, PB2, and PA, when they are ectopically expressed in cells. Interestingly, in contrast to HIV transcription, the kinase activity of CDK9 is not crucial for influenza virus transcription as overexpression of the dominant negative form of CDK9 does not reduce influenza virus transcription activity. In addition, the CDK9 inhibitor DRB does not affect viral transcription [120]. However, siRNA-mediated knockdown of cyclin T1 inhibits viral mRNA synthesis and overexpression of cyclin T1 promotes vRNP activity. It was suggested that interaction with P-TEFb facilitates vRNP association with cellular pol II for cap-snatching [121]. Thus, P-TEFb, not its kinase activity, plays an important role in regulating expression of the influenza A virus.

**P-TEFb co-operates with DENV-C to activate an inflammatory response**

Dengue virus (DENV) is a mosquito-transmitted RNA virus and is one of the most common infectious pathogens worldwide [122]. Viral infection results in dengue fever, dengue haemorrhagic fever, or dengue shock syndrome [123, 124]. At present, an effective dengue vaccine or anti-viral drug is not available. A notable issue that impedes dengue vaccine development is the limited understanding of the immunopathology of DENV infection. The DENV single-stranded RNA molecule is about 11 kb in size. It encodes three structural proteins (core protein, non-glycosylated membrane protein, and envelope protein) and seven non-structural proteins [125]. DENV infection is associated with increased levels of the inflammatory chemokines IL-8, IFN-γ, TNF-α, and TNF-β [126–128]. A recent finding has shed new light of the role of P-TEFb in the activation of IL-8 gene expression during DENV infection [129]. Li et al. [129] demonstrated that during DENV virus infection, P-TEFb associates with DENV core protein (DENV-C) to induce IL-8 expression. DRB treatment or siRNA-mediated knockdown of cyclin T1 prior to DENV infection abolishes the increase of IL-8 induction. P-TEFb and DENV-C core protein co-localize in vivo and co-immunoprecipitate in DENV-infected cells, and P-TEFb and DENV core proteins are recruited to the IL-8 gene. These findings further implicate the association of P-TEFb with DENV-C in altering host gene expression. The IL-8 gene promoter contains sites for the transcriptional activator NF-κB. Interestingly, in DENV-infected cells, the DENV-C protein appears to promote NF-κB-dependent activation only in the presence of P-TEFb [129]. The benefit to the virus of activating inflammation is unclear. However, the requirement of P-TEFb association with DENV-C to induce IL-8 expression in DENV-infected cells emphasizes the importance of P-TEFb in DENV immunopathogenesis and suggests that P-TEFb could be a valid drug target to treat some of the symptoms of DENV infection.

**CDK9 inhibitors as anti-viral agents**

The high mutation rate of viruses facilitates the emergence of strains resistant to drugs that target the virus directly, which represents a public health risk [130]. In addition to combating viral drug resistance, the alternative strategy of targeting cellular proteins used by viruses increases the potential range of targets and could yield drugs active against several viruses. Given the importance of P-TEFb for the replication of herpesviruses, HIV, HTLV, HAdV, influenza A virus and DENV, CDK9 and cyclin T are obvious potential drug targets. Drugs have already been developed that target P-TEFb for the treatment of disease. For example, CDK9 inhibitors are currently in clinical trials for the treatment of human malignancies [131].

Given the regulation of CDK9 by viral proteins during HSV, EBV, HCMV, and KSHV infections, the potential use of CDK9 inhibitors as anti-herpesvirus agents is particularly appealing. Acyclovir and its derivatives are effective, widely available, and have greatly reduced the burden of disease. However, the resistance to these drugs is becoming a major public health problem. The growing resistance is due to their frequent use in suppressive therapy and prophylaxis of HSV infection [132]. There is therefore a pressing need for the identification of potential herpesvirus drug targets to facilitate the development of the next generation of anti-herpesvirus drug. One of the most selective, non-competitive inhibitors of CDK9 is flavopiridol [133]. It was demonstrated that flavopiridol can suppress the replication of HSV, HCMV, HAdV, and HIV [88, 134]. In HeLa cells, the anti-HIV activity of CDK9 inhibitors, including flavopiridol, correlates with a dose-dependent loss of the large form of P-TEFb and reduction in HIV-1 infectivity. Unfortunately, studies in primary cell cultures indicate that cytotoxicity of the drugs used is a major drawback [135]. Interestingly, studies by Salerno et al. [136] demonstrated that effects of dominant negative CDK9 and flavopiridol are not equivalent. However, the next generation of small pharmacological compounds targeting CDK9 includes some promising anti-HIV therapeutic agents.

Roscovitine, a purine-derived CDK inhibitor, inhibits replication of HSV, HCMV, and HIV [137–139]. Roscovitine also reduces tumor size and plasma EBV DNA in patients with nasopharyngeal carcinoma [140]. Unfortunately, these inhibitors affect a wide range of CDKs and often negatively affect cell cycle progression [141]. It was recently demonstrated that R22, a novel selective CDK9 inhibitor, possess anti-cytomegaloviral activity [67]. In addition, a new CDK9 inhibitor (FIT-039) that exhibits an anti-viral effect on DNA and RNA viruses was identified [118]. It was shown to inhibit the replication of DNA viruses such as HSV-1, HSV-2, HAdV, and HCMV in cultured cells. Furthermore, FIT-039 also suppresses the replication of influenza virus H1N1 and of HIV. Interestingly, FIT-039 has a less significant effect on the cellular transcriptome than flavopiridol, and it does not affect cellular proliferation [118]. It is therefore a prospective drug that affects a broad spectrum of viruses.

**Concluding remarks**

P-TEFb is an important regulator of cellular processes, and it is functionally integrated into the expression of many human viruses. In particular, the activity of CDK9 is crucial for the course of HSV, HCMV, EBV, HIV, HTLV, HAdV, DENV, and KSHV virus infection.

P-TEFb is therefore a key player not only in cellular processes but also in viral biology (Fig. 6). Either by modifying its activity or regulating the amount of active and inactive complexes of P-TEFb and/or physical interaction with components
of P-TEFb, viruses have evolved strategies to hijack this key factor via their own regulatory proteins and P-TEFb functions as a central player in virus-host interaction to facilitate the viral replication cycle. Importantly, studies of viruses that use P-TEFb as a specific factor for efficient transcription will also help to elucidate the molecular mechanisms controlling transcription in uninfected cells.

Acknowledgements

We would like to thank Michael Tellier, Ivan Ferrer-Vicens, and Gabriel Klobusovsky for discussions and critical comments. This work was supported by Wellcome Trust (WT106134A) and Sir Edward Penley Abraham Trust Fund grants (EPA-RF202) to SM and a scholarship from the Malaysian Government to NFI.†

†Thomas et al. [146] have shown that the NSs protein of Bunyamwera virus (BUNV) can also affect phosphorylation of Ser2 of the pol II CTD. It is therefore possible that NSs also interacts with P-TEFb.

References

1. Spencer CA, Dahmus ME, Rice SA. 1997. Repression of host RNA polymerase II transcription by herpes simplex virus type 1. J Virol 71: 2031–40.
2. Cramer P. 2002. Common structural features of nucleic acid polymerases. Bioessays 24: 724–9.
3. Corden JL. 1990. Tails of RNA polymerase II. Trends Biochem Sci 15: 383–7.
4. McCracken S, Fong N, Yankulov K, Ballantyne S, et al. 1997. The C-terminal domain of RNA polymerase II couples mRNA processing to transcription. Nature 385: 357–61.
5. Bentley DL. 2014. Coupling mRNA processing with transcription in time and space. Nat Rev Genet 15: 163–75.
6. Bentley DL. 2005. Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors. Curr Opin Cell Biol 17: 251–6.
7. Phatnani HP, Greenleaf AL. 2006. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev 20: 2922–36.
8. Buratowski S. 2003. The CTD code. Nat Struct Biol 10: 679–80.
9. Saunders A, Core LJ, Lis JT. 2006. Breaking barriers to transcription elongation. Nat Rev Mol Cell Biol 7: 557–67.
10. Egloff S, Murphy S. 2008. Cracking the RNA polymerase II CTD code. Trends Genet 24: 280–8.
11. Egloff S, Dienstbier M, Murphy S. 2012. Updating the RNA polymerase II CTD code: adding gene-specific layers. Trends Genet 28: 333–41.
12. Eick D, Geyer M. 2013. The RNA polymerase II carboxy-terminal domain (CTD) code. Chem Rev 113: 8456–90.
13. Yamaguchi Y, Takagi T, Wada T, Yano K, et al. 1999. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 97: 41–51.
24. Bagella L, Herget GW. 2006. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J Biol Chem 281:12383–8.

25. Marshall NF, Price DH. 1992. Control of formation of two distinct classes of RNA polymerase II elongation complexes. Mol Cell Biol 12:2078–90.

26. Claudio PP, Cui J, Ghatourri M, Mariano C, et al. 2006. Cdk9 phosphorylates p53 on serine 392 independently of CKD. J Cell Physiol 208:602–12.

27. Radhakrishnan SK, Gartel AL. 2006. CDK9 phosphorylates p53 on serine residues 33, 315 and 392. Cell Cycle 5:159–21.

28. Grana X, De Luca A, Sang N, Fu TJ, et al. 2014. PITALRE, a nuclear CDCC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A 91:3834–8.

29. Garriga J, Segura E, Mayol X, Grumbeyer C, et al. 1996. Phosphorylation site specificity of the CDCC2-related kinase PITALRE. Biochem J 320:983–9.

30. Bagella L, Macalachlan TK, Buono RJ, Pisano MM, et al. 1998. Cloning of murine CDCK/PITALRE and its tissue-specific expression in development. J Cell Physiol 177:205–13.

31. Shore SM, Sang N, Fu TJ, et al. 2012. Herpes simplex virus type 1 P22P deletion mutant is altered for virulence and latency in vivo. Arch Virol 159:111–9.

32. Weir JP. 2001. Regulation of herpes simplex virus gene expression. Gene 271:117–30.

33. Honess RW, Roizman B. 1974. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 14:9–16.

34. Guo L, Wu WJ, Liu LQ, Wang LC, et al. 2012. Herpes simplex virus 1 P22P inhibits the transcription of viral protein promoters by binding to and blocking the recruitment of P-TEFb. PLoS One 7:e45749.

35. Fraser KA, Rice SA. 2007. Herpes simplex virus immediate-early protein ICP22 blocks loss of serine 2-phosphorylated RNA polymerase II. J Virol 81:5091–101.

36. Rice SA, Long MC, Lam V, Spencer CA. 1994. RNA polymerase II is aberrantly phosphorylated and localized to viral replication compartments following herpes simplex virus infection. J Virol 68:988–1001.

37. Long MC, Leong V, Schaffer PA, Spencer CA, et al. 1999. ICP22 and the UL13 protein kinase are both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II. J Virol 73:5593–604.

38. Zaborowska J, Bauml S, Laimer C, O’Reilly D, et al. 2014. Herpes Simplex Virus 1 (HSV-1) ICP22 protein directly interacts with cyclin-dependent kinase (CDK9) to inhibit RNA polymerase II transcription elongation. PLoS One 9:e97654.

39. Rutkowski AJ, Erhard F, L’Hernault A, Bonfert T, et al. 2015. Widespread disruption of host transcription termination in HSV-1 infection. Nat Commun 6:7126.

40. Mostafa H, Davido DJ. 2013. Herpes simplex virus 1 ICP22 but not US 1.5 is required for efficient acute replication in mice and VICE domain formation. J Virol 87:13510–9.

41. Maruzuru Y, Fuji H, Oyama M, Kozuka-Hata H, et al. 2013. Roles of p53 in herpes simplex virus replication. J Virol 87:9323–32.

42. Chang Y, Cesarsman E, Pessin MS, Lee F, et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266:1865–9.

43. Soulier J, Grollot L, Oksenhendler E, Cacoub P, et al. 1995. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86:1276–80.

44. Nador RG, Cesarsman E, Chadburn A, Dawson DB, et al. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 88:645–56.

45. Godden-Kent D, Talbot SJ, Boshoff C, Chang Y, et al. 1997. The cyclin encoded by Kaposi’s sarcoma-associated herpesvirus stimulates cyclin D1 to phosphorylate the retinoblastoma protein and histone H1. J Virol 71:4193–8.

46. Ojala PM, Tieninen M, Salven P, Veikola T, et al. 1999. Kaposi’s sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6. Cancer Res 59:4984–9.

47. Chang PC, Li M. 2008. Kaposi’s sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor. J Virol 82:278–80.

48. Tsai WH, Wang PW, Lin SY, Wu IL, et al. 2012. Ser-634 and Ser-636 of Kaposi’s sarcoma-associated herpesvirus RTA are involved in transactivation and are potential cdk9 phosphorylation sites. Front Microbiol 3:60.

49. Toth Z, BrulorisKF, Wong LY, Lee HR, et al. 2012. Negative elongation factor-mediated suppression of RNA polymerase II elongation of Kaposi’s sarcoma-associated herpesvirus lytic gene expression. J Virol 86:9696–707.

50. Fortunato EA, McClay OK, Sanchez I, Spector DH. 2000. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. Trends Microbiol 8:111–17.

51. Zhou YF, Leon MB, Wacławski MA, Popma JJ, et al. 1996. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 335:624–30.

52. Ahn JH, Jang WJ, Hayward GS. 1999. The human cytomegalovirus IE2 and UL112-113 proteins accumulate in viral DNA replication compartments that initiate from the periphery of promyelocytic leukemia protein-associated nuclear bodies (PODs of ND10). J Virol 73:10458–71.

53. Ibrahim AM, Sweeney M, Maud GG. 1997. Human cytomegalovirus immediate early interaction with host nuclear structures: definition of an immediate transcript environment. J Cell Biol 138:5–16.

54. Kapasi AJ, Spector DH. 2008. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically

55. J Cell Biol 116, © 2015 The Authors. Inside the Cell published by WILEY Periodicals, Inc.
alters the levels and localization of the RNA polymerase II carboxy-terminal domain kinases CDK9 and CDK7 at the viral transcriptosomes. J Translational Medicine 2015; 13: 92–4.

67. Feichtinger S, Stammlinger T, Muller R, Graf L, et al. 2011. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral UBF and cyclin T1. J Virol 85: 1519–31.

68. Tamrakar S, Kapasi AJ, Spector DH. 2005. Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxy-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of CDK9 and CDK7. J Virol 79: 15477–93.

69. Kapasi AJ, Clark CL, Tran K, Spector DH. 2009. Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding of cyclin T1, a threshold level of IE2 66, and active transcription. J Virol 83: 5904–17.

70. Graf L, Weibel R, Wagner S, Hamilton ST, et al. 2013. The cyclin-dependent kinase ortholog pUL97 of human cytomegalovirus interacts with cyclins. Virology. 321:33–50.

71. Richman DD, Bhardwaj N, Roeder GS, et al. 2015. Gene target specificity of the super elongation complex (SEC) family: how HIV-1 Tat employs selected SEC members to activate viral transcription. Nucleic Acids Res 43: 8868–79.

72. Tahirih TH, Babayeva ND, Varzavand K, Cooper JJ, et al. 2010. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 465: 747–51.

73. Wu Y, Babayeva ND, Suwa Y, Baranovsky AG, et al. 2014. Crystal structure of HIV-1 Tat complexed with P-TEFb and AFF4. Cell Cycle 13: 1788–97.

74. Kira J, Itoyama Y, Koyanagi Y, Tateishi J, et al. 1992. Presence of HTLV-I proviral DNA in central nervous system of patients with HTLV-I-associated myelopathy. Ann Neurol 31: 39–45.

75. Osame M, Usuku K, Izumo S, Ichii N, et al. 1986. HTLV-I-associated myelopathy, a new clinical entity. Lancet 1: 1031–2.

76. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. 1984. Monoclonal integration of human T-cell leukemia virus provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 81: 2534–7.

77. Morchuzki M, Watanabe T, Yamaguchi K, Tajima K, et al. 1992. Uvitis associated with human T lymphotropic virus type I: otorhinolaryngologic, clinical, and virologic studies. J Infect Dis 166: 943–4.

78. Bex F, Gaynor RB. 1998. Regulation of gene expression by HTLV-I Tax protein. Methods 16: 83–94.

79. Franklin AA, Nyborg JK. 1995. Mechanisms of Tax regulation of human T cell leukemia virus type I gene expression. J Biomed Sci 2: 17–29.

80. Zhou M, Lu H, Park H, Wilson-Chiu J, et al. 2006. Tax interacts with P-TEFb in a novel manner to stimulate human T-lymphotropic virus type I transcription. J Virol 80: 4781–91.

81. Cho WK, Zhou M, Jang MK, Huang K, et al. 2007. Modulation of the Brd4/P-TEFb interaction by the human T-lymphotropic virus type I tax protein. J Virol 81: 11179–85.

82. Cho WK, Jang MK, Huang K, Pise-Masison CA, et al. 2010. Human T-lymphotropic virus type 1 Tax protein complexes with P-TEFb and competes for Brd4 and 7SK snRNPs/HXH1M1 binding. J Virol 84: 1299–309.

83. Fuca TD, Byun JS, Wakano C, Fernandez A, et al. 2015. The Tax oncogene enhances ELL incorporation into p300 and P-TEFb containing protein complexes to activate transcription. Biochem Biophys Res Commun 465: 5–11.

84. Dominguez O, Rojo P, de Las Heras S, Folguera D, et al. 2005. Clinical presentation and characteristics of pharyngeal adenovirus infections. Pediatr Infect Dis J 24: 733–4.

85. Boyer TG, Martin ME, Lees E, Ricciardi RP, et al. 1999. Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein. Nature 399: 276–9.

86. Stevens JL, Cantin GT, Wang G, Shevchenko A, et al. 2002. Transcription control by E1A and MAP kinase pathway via Srb2 mediator subunit. Science 296: 755–8.

87. Vijayalingam S, Chinnadurai G. 2013. Adenovirus E1A activates transcription through mediator complex-dependent recruitment of the super elongation complex. J Virol 87: 3425–34.

88. Yamamoto M, Onogi H, Kii I, Yoshida S, et al. 2014. CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses. J Clin Invest 124: 4230–41.

89. Engelhardt OG, Smith M, Fodor E. 2005. Association of the influenza A virus RNA polymerase with cellular RNA polymerase II. J Virol 79: 8128–30.

90. Choi CY, Vreede FT, Smith M, Engelhardt OG, et al. 2006. Influenza virus inhibits RNA polymerase II elongation. Virology 351: 210–7.

91. Zhang J, Li G, Ye X. 2010. Cyclin T1/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II. J Virol 84: 12619–27.
124. Chambers TJ, Hahn CS, Galler R, Rice CM. 1990. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44: 649–88.

125. Chambers TJ, van Der Meer GM, Mackenzie JS, Gubler DJ, Petersen LR. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: 598–109.

126. Biglione S, Byers SA, Price JP, Nguyen VT, et al. 2007. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4: 47.

127. Thomas D, Blikogi G, Wagner V, Banholzer M, et al. 2004. Inhibition of RNA polymerase II phosphorylation by a viral interferon antagonist. J Biol Chem 279: 31471–7.

128. Clyde K, Kyle JL, Harris E. 2006. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 80: 11418–31.

129. Li Y, Wang Y, Zhu Q, Zhou R, et al. 2008. Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. J Virol 82: 10591–9.

130. Field HJ. 2001. Herpes simplex virus antiviral drug resistance—current trends and future prospects. J Clin Virol 21: 261–8.

131. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. 2008. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 29: 16–21.

132. Wang Y, Wang Q, Zhu Q, Zhou R, et al. 2011. Identification and characterization of acyclovir-resistant clinical HIV-1 isolates from children. J Clin Virol 52: 107–12.

133. Chao SH, Fujinaga K, Marion JE, Taube R, et al. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275: 28345–8.

134. Schang LM, St Vincent MR, Lacasse JJ. 2006. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother 17: 293–320.

135. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, et al. 2002. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50: 465–72.

136. Hsieh WS, Soo R, Peh BK, Loh T, et al. 2009. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 15: 1435–42.

137. Diwan P, Lacasse JJ, Schang LM. 2004. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. J Virol 78: 9352–65.

138. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, et al. 1998. Dengue and dengue haemorrhagic fever. Lancet 352: 971–7.

139. Juffrie M, van Der Meer GM, Hack CE, Haasnoot K, et al. 2000. Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun 68: 702–7.

140. Mitrou R, Correa R, Pecoraro D, et al. 2004. Spectrum of cdk-9 inhibitor activity against HIV-1 replication among various models of chronic and latent infection. Antivir Chem Chemother 12: 33–41.

141. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, et al. 2002. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50: 465–72.

142. Durand LO, Roizman B. 2008. Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. J Virol 82: 10591–9.

143. Rechter S, Scott GM, Eickhoff J, Zielke K, et al. 2009. Cyclin-dependent kinases phosphorylate the cytoplasmic flavivirus RNA export protein pUL69 and modulate its nuclear localization and activity. J Biol Chem 284: 8605–13.

144. Romano G, Kasten M, De Falco G, Micheli P, et al. 1999. Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression. J Cell Biochem 75: 357–68.

145. Zhou M, Halanski MA, Radonovich MF, Kashanchi F, et al. 2000. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxy-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol 20: 5077–86.

146. Hasham MG, Lee HH, van Der Meer GM, Mackenzie JS, Gubler DJ. 2004. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. J Virol 78: 9352–65.